IDH1, isocitrate dehydrogenase (NADP(+)) 1, 3417

N. diseases: 399; N. variants: 10
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0017638
Disease: Glioma
Glioma
0.700 Biomarker disease BEFREE IDH2 mutations were associated with better outcomes compared with IDH wild-type gliomas (P < 0.05). 31833906 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 Biomarker disease BEFREE Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma. 31824866 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 GeneticVariation disease BEFREE MATH values were increased in patients with glioma with the wild-type isocitrate dehydrogenase (NADP<sup>(+)</sup>) (IDH)1/2 (IDH-wt) gene (P=0.001) and glioblastoma (GBM; P=0.001). 31788085 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 Biomarker disease BEFREE Novel IDH1-Targeted Glioma Therapies. 31768950 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 Biomarker disease BEFREE Mutation of the isocitrate dehydrogenase (IDH) gene is regarded a novel indicator for the prognosis of patients with glioma. 31746408 2020
CUI: C0017638
Disease: Glioma
Glioma
0.700 AlteredExpression disease BEFREE In this study, we investigated the relationship between SWI features and glioma grades, and the expression of key molecular markers isocitrate dehydrogenase 1 (IDH1), O-6-methylguanine-DNA methyltransferase (MGMT), and 1p19q. 31745161 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 GeneticVariation disease BEFREE In this study, using bioinformatics algorithms, we examined the chemical relationships between the amino acid sequences of the complementarity-determining region-3 (CDR3) represented by immune receptors associated with lower grade glioma and isocitrate dehydrogenase-1 (IDH1) mutants. 31740784 2020
CUI: C0017638
Disease: Glioma
Glioma
0.700 GeneticVariation disease BEFREE For patients with IDH mutant 1p/19q codeleted LGG tumors, there is limited evidence to support the use of TMZ. 31701682 2020
CUI: C0017638
Disease: Glioma
Glioma
0.700 GeneticVariation disease BEFREE IDH1/2 mutation status now represents the most important initial stratifier of diffuse gliomas in adults, although rarer subtypes within the IDH-wildtype category continue to be elucidated. 31678207 2020
CUI: C0017638
Disease: Glioma
Glioma
0.700 Biomarker disease BEFREE A nomogram incorporating radiomics signature, IDH and age improved the performance of OS estimation, which might be a new complement to the treatment guidelines of glioma. 31606714 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 Biomarker disease BEFREE An analysis of 2589 patient samples showed that CLEC5A expression is higher in (1) glioblastoma than in lower-grade glioma and nontumor tissue, (2) in the mesenchymal subtype than in other subtypes, and (3) in IDH1-wild type glioblastoma than in IDH1-mutated glioblastoma. 31591460 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 GeneticVariation disease BEFREE Blockade of glutathione metabolism in IDH1-mutated glioma. 31548295 2020
CUI: C0017638
Disease: Glioma
Glioma
0.700 GeneticVariation disease BEFREE This theory also provides an explanation for some of the most perplexing observations, including the scarcity of proper model systems and the prevalence of IDH1 mutation in glioma. 31504231 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 Biomarker disease BEFREE The review also focuses on the effect of 2-HG on glioma epigenetics, the cellular signaling involved in IDH1 mutant glioma cells and the therapeutic response seen in mutant IDH1(mIDH1) harboring glioma patients in comparison to the patients with wild-type IDH1. 31485826 2020
CUI: C0017638
Disease: Glioma
Glioma
0.700 GeneticVariation disease BEFREE Multivariate analysis incorporating tumor status based on the presence of <i>IDH</i> mutations, <i>TERT</i> promoter mutations, and 1p/19q codeletion showed that in lower-grade gliomas, high NLR predicted poorer survival for the triple-negative, IDH mutation only, TERT mutation only, and IDH and TERT mutation groups. 31444316 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 GeneticVariation disease BEFREE PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival. 31324855 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 GeneticVariation disease BEFREE IDH1/2 active site mutations confer a neomorphic enzyme activity producing the oncometabolite D-2-hydroxyglutarate (D-2HG), which generates the glioma CpG island methylation phenotype (G-CIMP). 31292202 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 GeneticVariation disease BEFREE In clinical samples of gliomas with IDH1 mutation, levels of D-2-hydroxyglutarate (D-2HG) were increased significantly compared with gliomas without IDH mutation. 31278288 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 GeneticVariation disease BEFREE Mutations in the isocitrate dehydrogenase-1 gene (IDH1) occur at high frequency in grade II-III gliomas (LGGs). 31240524 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 GeneticVariation disease BEFREE Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers. 31222125 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 Biomarker disease BEFREE IDH Inhibitors Target Common Glioma Mutation. 31217295 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 AlteredExpression disease BEFREE CD163 expression was up-regulated in IDH wild-type glioma and mesenchymal subtype. 31143523 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 GeneticVariation disease BEFREE There is variability in survival within IDH mutant gliomas determined by chromosomal events. 31134296 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 Biomarker disease BEFREE Therefore, MET uptake for glioma grading was more consistent for IDH1-wildtype tumours than for IDH1-mutant tumours. 31102001 2019
CUI: C0017638
Disease: Glioma
Glioma
0.700 AlteredExpression disease BEFREE Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative Period. 31100523 2019